medicare glp-1 coverage obesity CMS Extends Medicare's Short-Term Bridge Program for Drug Medicare now covers GLP-1s for

Breastfeeding parents need an average of at least 500 additional calories daily, and GLP-1s can significantly decrease appetite and compromise energy and nutrition

The pharmacokinetic properties of liraglutide enable 24-h exposure coverage, a requirement for 24-h glycaemic control with once-daily dosing

Nausea affects up to 20% of semaglutide users and is the most common reason people discontinue treatment (Alhazmi & le Roux 2026, Frontiers in Endocrinology)

GLP-1R-targeted nanomedicines often carry multifunctional payloads, such as GLP-1 analogs, chemotherapeutic agents, and diagnostic compounds, which do not conform to conventional monotherapy trial frameworks [558, 559]

Prospective studies, such as the UK Prospective Diabetes Study (UKPDS) demonstrated that T2D is a progressive disease that worsens over time, whatever the pharmacological management used to reduce daily glucose excursion

Patients who are taking concomitant diabetes medications should monitor their blood sugars closely and be prepared to treat hypoglycemia (see hypoglycemia for more) Injection site reactions Injection site reactions, including pruritus, erythema, inflammation, induration, and irritation, may occur